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Abstract
Gastroesophageal reflux disease (GERD) is a common 
disorder of the gastrointestinal tract. In the last few 
decades, new technologies have evolved and have 
been applied to the functional study of the esophagus, 
allowing for the improvement of our knowledge of the 
pathophysiology of GERD. High-resolution manometry 
(HRM) permits greater understanding of the function of 
the esophagogastric junction and the risks associated 
with hiatal hernia. Moreover, HRM has been found to 
be more reproducible and sensitive than conventional 
water-perfused manometry to detect the presence 
of transient lower esophageal sphincter relaxation. 
Esophageal 24-h pH-metry with or without combined 
impedance is usually performed in patients with 
negative endoscopy and reflux symptoms who have 
a poor response to anti-reflux medical therapy to 
assess esophageal acid exposure and symptom-reflux 
correlations. In particular, esophageal 24-h impedance 
and pH monitoring can detect acid and non-acid reflux 
events. EndoFLIP is a recent technique poorly applied 
in clinical practice, although it provides a large amount 
of information about the esophagogastric junction. 
In the coming years, laryngopharyngeal symptoms 
could be evaluated with up and coming non-invasive or 
minimally invasive techniques, such as pepsin detection 
in saliva or pharyngeal pH-metry. Future studies are 
required of these techniques to evaluate their diagnostic 
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accuracy and usefulness, although the available data 
are promising.
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Core tip: In the last few decades, new technologies have 
evolved and have been applied to the functional study 
of the esophagus, allowing for the improvement of our 
knowledge of the pathophysiology of gastroesophageal 
reflux disease. High-resolution manometry permits a 
greater understanding of the function of the esopha-
gogastric junction and the risks associated with hiatal 
hernia. The Chicago Classification V3.0 could define a 
hierarchic classification that accurately defines the major 
and minor disorders of esophageal motility. Esopha-
geal 24-h pH-metry, especially when it is combined 
with impedance, is usually performed in patients with 
negative endoscopy and reflux symptoms who have 
a poor response to anti-reflux medical therapy to ass-
ess esophageal acid exposure and symptom-reflux 
correlations. In particular, esophageal 24-h impedance 
and pH monitoring are able to detect acid and non-
acid reflux events. EndoFLIP is a recent technique 
poorly applied in clinical practice, although it provides a 
large amount of information about the esophagogastric 
junction. Recently, up and coming non-invasive or 
minimally invasive techniques, such as pepsin detection 
in saliva or pharyngeal pH-metry, have been suggested 
to detect laryngopharyngeal reflux disease. Future 
studies are required for these techniques to evaluate 
their accuracy and usefulness, although the available 
data are promising.
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INTRODUCTION
Gastroesophageal reflux disease (GERD) is a highly 
prevalent disease in Western countries, affecting up to 
20% of the general population, with important impacts 
on health care costs and the quality of life of patients[1]. 
According to the Montreal Definition, GERD develops 
when the reflux of gastric contents causes troublesome 
symptoms and/or complications[2,3]. 
In the past decade, it was realized that, in addition 
to the presence of esophageal mucosal lesions (i.e., 
erosions, intestinal metaplasia), the majority of GERD 
patients (approximately 70%) have typical reflux 
symptoms (i.e., heartburn, regurgitation) without any 
esophageal mucosal breaks on upper endoscopy; 
thus, they are considered to have non-erosive reflux 
disease (NERD)[2,4]. In keeping with this definition, a 
GERD diagnosis can be based on the presence of typical 
symptoms only. In contrast, several recent studies have 
emphasized that NERD represents a heterogeneous 
group of patients with several pathophysiological and 
clinical differences, and it should be better classified 
using appropriate techniques able to characterize 
gastro-esophageal refluxate because the management 
and therapeutic response can change on the basis 
of the main mechanisms of symptom generation[5-7]. 
Conventional pH monitoring was first considered a 
useful tool to identify GERD patients, by evaluating 
distal esophageal acid exposure time (AET), number 
of acid reflux episodes and the association between 
symptoms and acid reflux[8,9]. However, the growing 
acknowledgment that factors/stimuli different from 
acid were involved in symptom generation in GERD 
has paved the way toward the search for innovative 
diagnostic and therapeutic approaches to GERD[10]. 
Moreover, the more frequent request to evaluate patients 
refractory to therapy with proton pump inhibitors (PPIs) 
has provided further impetus in this direction[11-13]. 
Finally, it is relevant to bear in mind the increasing re-
ferral to our outpatient clinics of subjects with extra-
esophageal symptoms suggestive of GERD, such as 
laryngeal and pulmonary symptoms, representing a true 
challenge in our clinical practice due to the difficulties in 
evaluating the potential relationship of their symptoms 
and GERD with appropriate management[14,15]. In 
this context, the advent of novel esophageal function 
testing, such as impedance-pH monitoring (MII-pH) 
and high resolution manometry (HRM), has allowed 
for relevant progress in the understanding of the 
pathophysiological mechanisms contributing to the 
development of GERD and, thereafter, its diagnosis and 
management. Moreover, the role of new technology to 
detect laryngopharyngeal reflux (LPR)[16-18], as well as 
the presence of pepsin in clinical samples[19], deserves 
careful consideration. The aim of the present review 
article is to report on the current literature about recent 
advances in diagnosing GERD.
HIGH RESOLUTION MANOMETRY
GERD is primarily a motility disorder in which impair-
ment of the esophago-gastric junction (EGJ) and 
ineffective esophageal motility (IEM) play an important 
roles[20-26]. 
Esophageal manometry, which assesses intraluminal 
esophageal pressures, peristalsis and bolus transit, is 
currently considered the gold standard to detect the esop-
hageal motility abnormalities. Conventional manometry 
techniques record esophageal peristalsis using a catheter 
with 5 to 8 water-perfused channels, with or without a 
sleeve sensor to measure continuously the maximum 
lower esophageal sphincter (LES) pressure. 
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HRM was described for the first time in 1991, 
introducing an increased number of pressure sensors 
along the catheter and the use of spatio-temporal 
plots[27,28], leading to the subsequent development of the 
Chicago Classification for primary esophageal motility 
disorders[29,30]. In HRM systems, multiple sensors (up 
to 36) are distributed longitudinally and radially, closely 
spaced along the length of the manometric catheter. 
Two main types of manometric catheters are currently 
available, solid state and water perfused, each with 
different physical and performance characteristics and 
specific advantages and disadvantages concerning 
costs, preparation, the location of transducers, auto-
clave possibility and the rate of pressure increase. 
Nevertheless, HRM allows for simultaneous pressure 
readings within both the sphincters and the esopha-
geal body, providing detailed esophageal pressure 
topography (EPT) (Figure 1). With HRM, pull-through 
techniques became unnecessary and several problems, 
such as artifacts attributable to swallow-induced 
sphincter movement[31] or EGJ conformational changes 
that can spontaneously occur, were overcome[32-34]. 
RM provides a dynamic representation of the pressure 
within and across the EGJ, and it also creates oppor-
tunities to quantify more precise measurement of 
EGJ relaxation and morphology[25,26,31], providing the 
opportunity to detect expiratory LES pressure and crural 
diaphragm (CD) contraction[35-39]. On this basis, the EGJ 
was recently reviewed and classified into three types: 
Type Ⅰ (no LES-CD separation); type Ⅱ (the LES and 
CD are spatially separated such that there is a double-
peaked pressure profile, but the nadir pressure between 
LES and CD does not decrease to gastric pressure); an 
type Ⅲ (the separation between peaks is > 2 cm, and 
the nadir pressure between LES-CD is equal to or less 
than the gastric pressure; in type Ⅲa, the pressure 
inversion point is located at the CD, while in type Ⅲb, it 
is placed at the LES level[30,36]. 
Pandolfino et al[36] compared the EPT attributes of 
the EGJ between 156 GERD patients and 75 asympto-
matic controls. Although both lower LES pressure and 
greater LES-CD separation were associated with GERD, 
impaired CD function was most strongly associated 
factor and the only independent predictor of GERD. A 
study designed to analyze the relationship between 
obesity and the morphology of the EGJ pressure 
segment showed that obese subjects were more likely 
to have a spatial separation between the diaphragm and 
LES (Figure 2) and an augmented gastroesophageal 
pressure gradient[37]. These findings might partially 
explain why gastro-esophageal reflux is more frequent 
in obese subjects, as also evidenced in patients with 
NERD[40]. Bredenoord et al[32] showed that, in cases of 
small hiatal hernias in which intermittent reduction of 
the hernia frequently occurs, spatial separation of the 
CD and LES in the non-reduced state resulted in a 2-fold 
increase in acid and weakly acidic reflux. 
Transient LES relaxations (TLESRs) are the most 
common mechanism of reflux. They occur independently 
from swallowing and are not accompanied by peristalsis, 
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Figure 1  High resolution pressure topography of a peristaltic wave. In the picture, both the upper and lower esophageal sphincters and swallowing-induced 
relaxation of the lower esophageal sphincter are well represented. UES: Upper esophageal sphincter; LES: Lower esophageal sphincter.
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as 5 or more ineffective swallows of 10 with a DCI thre-
shold of 450 mmHg-s-cm. No distinction need be made 
between failed swallows (DCI < 100 mmHg-s-cm) and 
weak swallows (450 mmHg-s-cm)[30].
Multiple rapid swallowing (MRS) as a provocative 
test has been suggested to diagnose IEM (in borderline 
conditions). MRS consists of administering 2 mL of water 
five times, for a total amount of 15 mL of water, in less 
than 10 s. MRS inhibits the esophageal body and LES 
during the first four swallows, and it is normally followed 
by an esophageal contraction of increased amplitude. It 
was suggested that many patients with suspected IEM 
had normalized esophageal contraction amplitude after 
MRS[47].
Manometric studies have described decreased 
pressure between striated and smooth esophageal mus-
cle[48]. Pohl et al[49] correlated the size of the esophageal 
low-pressure zone and its possible relationship with 
esophageal symptoms (dysphagia, chest pain, and 
heartburn/regurgitation). 
In conclusion, HRM is faster and easier to perform 
than conventional water-perfused manometry. Moreover, 
HRM does not require time-consuming pull-through 
maneuvers, and it allows for accurate evaluation of 
the intrinsic and extrinsic components of EGJ, thus 
improving the identification of TLESRs. However, the 
clinical application of this technique in GERD remains 
very limited; TLESRs cannot be used in the diagnosis 
of GERD because their prevalence is similar between 
GERD patients and normal subjects. Furthermore, minor 
but they are accompanied by diaphragmatic inhibition, 
and they persist for longer periods than swallow-
induced LES relaxations (> 10 s)[41,42]. In a recent 
study, Roman et al[43] demonstrated that HRM is re-
producible and more sensitive than perfused-sleeve 
manometry to detect TLESRs, providing better inter-
observer agreement. Notably, in GERD patients, there 
is not an increased frequency of TLESR compared with 
controls but only a greater frequency of acid reflux 
during TLESRs[44]. Bredenoord et al[45] investigated the 
factors associated with reflux during TLESRs but no 
differences were observed in TLESR duration, trans-
sphincteric pressure gradient, the prevalence, duration 
and amplitude of esophageal pre-contractions or 
sphincteric post-contractions. Pandolfino et al[35] studied 
the largest number of TLESRs in the postprandial period. 
They observed that the key events associated with 
EGJ opening were CD inhibition, LES relaxation, distal 
esophageal muscular contraction and a positive gradient 
between the stomach and the esophagus, but in only 
a few cases was manometric signature of EGJ opening 
associated with evidence of reflux on pH-metry.
It has been shown that 21%-38% of patients with 
GERD present with severely impaired esophageal 
peristalsis (Figure 3), resulting in more severe reflux, 
slower acid clearance, worse mucosal injury, and 
more frequent respiratory symptoms[46]. The Chicago 
Classification V3.0 approved the term “IEM”, which is 
frequently used in conventional manometry[30]. In this 
recent Chicago Classification version, IEM was defined 
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Figure 2  High resolution pressure topography at 30 s resting pressure calculation. In the picture, both the upper and lower esophageal sphincters and the 
crural diaphragm are well represented. This picture represents a large hiatal hernia (5 cm). UES: Upper esophageal sphincter.
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esophageal motility abnormalities, observed in GERD 
patients, are not specific and can either be primarily 
or secondarily related to GERD[50]. However, HRM 
represents an important advance in the assessment of 
esophageal motor function and a promising technique 
for the evaluation of the mechanical abnormalities 
involved in GERD. Further studies are needed to eva-
luate additional possible benefits of this technique in 
clinical practice.
MULTICHANNEL INTRALUMINAL 
IMPEDANCE AND PH
Multichannel intraluminal impedance (MII) has been 
promoted to detect the movement of fluid, solid, and air 
in the esophagus regardless of its pH[51]. 
This new device, which combines MII-pH analysis, 
provides a sophisticated characterization of reflux 
episodes over a 24-h period. The most common cathe-
ter allows for 6 channels for intraluminal impedance (at 
3, 5, 7, 9, 15, and 17 cm) and a pH sensor (at 5 cm 
above the upper border of the LES)[52]. 
MII-pH is an innovative technique that provides a 
detailed characterization of each reflux event including 
chemical (acid and non-acid reflux) and physical pro-
perties (liquid, mixed, gas) (Figure 4)[53]. To date, non-
acid reflux represents the majority of reflux episodes 
in patients with GERD on PPI therapy[54,55]. Indeed, the 
total number of reflux episodes is not affected by acid 
suppressive therapy, and weakly acidic reflux accounts 
for approximately 90% of all reflux episodes in patients 
on PPIs, thus representing a potential mechanism under-
lying the failure of PPI treatment in patients with reflux-
related symptoms[56,57]. Moreover, MII-pH monitoring, 
as well as pH-metry alone, provides the opportunity 
to assess the temporal relationship between the oc-
currence of refluxes and the onset of symptoms[58,59]. 
The relationship between symptoms and reflux events 
can be evaluated with the symptom index (SI) and 
symptom association probability (SAP), which are the 
most commonly used symptom indices[59]. 
Based on esophageal pH monitoring, NERD patients 
with physiological esophageal AET and a close temporal 
relationship between symptoms and reflux events have 
been defined as hypersensitive to acid stimuli. In con-
trast, in agreement with the Rome Ⅲ criteria, patients 
with heartburn, normal upper endoscopy, physiological 
AET, and negative correspondence between symptoms 
and reflux and who fail to respond to PPIs are defined 
as having functional heartburn (FH)[8,9,60]. In this regard, 
the advent of MII-pH monitoring has improved the dia-
gnostic yield of GERD patients, mainly by identifying 
a positive SAP or SI with weakly acidic or non-acid 
reflux[61-68]. In particular, if pH-metry and the patient’s 
response to PPI therapy are compared with MII-pH, we 
can observe an underestimation of GERD patients[69,70]. 
In contrast, all of the available diagnostic tests for 
GERD have some limitations. The drawbacks of MII-
pH are mainly due to the day-to-day variability of the 
test[71-73]. Additionally, the reflux-symptom correlation in 
patients with GERD who do not respond to PPI therapy 
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Figure 3  High resolution pressure topography of a weak peristaltic wave (distal contractile integral 110 mmHg-s-cm). UES: Upper esophageal sphincter; 
LES: Lower esophageal sphincter; DCI: Distal contractile integral.
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is actually also calculated by the SI or SAP if its validity 
is still uncertain[74,75]. Recently Zerbib et al[76] reported 
that MII-pH findings were not always able to predict the 
response to PPIs in patients with typical reflux-related 
symptoms when the test is performed off PPI therapy.
Regarding the clinical utility of pathophysiological 
investigations in patients with heartburn, we described 
a group of patients (more than 19% of the whole 
population enrolled) with heartburn who completely 
responded to PPI, in whom GERD was not diagnosed 
with the MII-pH test[5]. Thus, our data suggested that 
PPI response alone should not be always considered 
a good predictor of a GERD diagnosis[5]. Overall, it is 
notable that NERD patients vary greatly from a pathoph-
ysiological point of view and should be accurately studied 
by means of MII-pH to undertake the best therapeutic 
approach[6]. Indeed, a meta-analysis found that the once 
defined low response rate in NERD was likely the result 
of the inclusion of patients with heartburn who did not 
have reflux disease[77]. 
Recently, the ability to perform MII-pH testing to 
understand GERD pathophysiology better has improved 
through the introduction of up and coming parameters, 
such as the post-reflux swallow-induced peristaltic wave 
(PSPW) index, which indicates the efficacy of esophageal 
clearance[78], and baseline impedance values, which 
indicate the presence of a lack of integrity in the esop-
hageal mucosa[79]. Constant changes in esophageal 
chemical clearance could represent a specific mechanism 
involved in GERD pathophysiology. PSPW has been 
shown to be lower in patients with abnormal AET, 
compared to healthy volunteers (HVs) or FH patients. 
Moreover, this parameter was not altered after medical 
or surgical therapy[78]. Further, Kessing et al[80] described 
lower values of baseline impedance levels in the distal 
esophagus of patients with abnormal esophageal AET, 
compared to HVs. The authors described a negative 
correlation between baseline impedance levels and 
esophageal AET[80]. We recently described a large group 
of patients with typical GERD symptoms, negative 
endoscopy and any pathophysiological characteristics 
of GERD (normal AET, number of refluxes and negative 
SI and SAP). We observed that patients with good 
symptom relief after PPI therapy had lower baseline 
impedance values than FH patients (non-responders). 
FH patients showed similar baseline values to HVs. 
Moreover, we observed almost the same results 
when analyzing the PSPW index, which was lower in 
responders than in non-responders and HV groups. A 
direct linear correlation between PSPW and baseline 
impedance values has been described. Overall, these 
data suggest that baseline impedance values and PSPW 
could be considered up-and-coming parameters that 
could be helpful in better investigating patients with 
GERD-related symptoms, particularly when symptom-
reflux association indexes fail to do so[81]. 
MII-pH testing showed that acid reflux events and 
their clearance were determinant factors that provoked 
esophageal mucosal breaks. Non-acid reflux does not 
appear to be directly related to the development of 
esophageal mucosa lesions; however, it is definitely 
involved in the genesis of symptoms in both NERD and 
erosive esophagitis (EE) patients. Ambulatory MII-pH 
studies have suggested that patients with moderate or 
severe esophagitis have rates of weakly acidic reflux 
similar to or slightly greater than healthy controls[69]. 
In this regard, it is important to emphasize that weakly 
acidic reflux is not synonymous with bile reflux. A 
simultaneous Bilitech and MII-pH study showed no 
relationship between the percentage of time for bilirubin 
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Figure 4  Graphic representation of MII-pH reflux events: (A) acid-proximal reflux; (B) non-acid distal reflux. Z1-Z6: Impedance channel; pH: Channel for pH 
recording.
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absorbance and weakly acidic or weakly alkaline reflux. 
Indeed, this study showed that the greatest number of 
bile refluxes occurred concomitantly with acid refluxes[82]. 
In patients with Barrett’s esophagus (BE), MII-
pH testing showed overall more severe reflux disease 
with a greater number of acid and weakly acidic reflux 
events and higher proximal extension[71]. By means 
of MII-pH, Savarino et al[71] showed that patients with 
BE and EE had greater numbers of acid and weakly 
acidic reflux episodes, higher percentages of proximal 
migration of the refluxate and higher total acid and 
volume clearance. Notably, it has been emphasized 
that a significantly increased amount of total reflux 
occurs in both the long and short segments of BE, com-
pared with EE. In BE patients, the MII-pH tracks are 
not easy to analyze, especially in the long segment 
of BE. Inflammation and histologic modifications are 
supposed to reduce baseline impedance values thus 
impairing the ability to detect the real number of reflux 
episodes. This phenomenon has led some investigators 
to be more accurate during the manual analysis of MII-
pH in patients with BE[62]. However, some authors have 
shown the viability of MII-pH even in BE patients[71,83]. 
In clinical practice, BE patients should be evaluated with 
MII-pH “on” PPI therapy to evaluate the effectiveness of 
acid suppression. 
The presence of EE, which represents clear endo-
scopic evidence of esophageal mucosal injury (30% 
of all endoscopic series in patients with GERD-related 
symptoms), can obviously be responsible for symptoms 
provoked by the refluxate. In contrast, the absence 
of macroscopic damage makes it difficult to clarify 
the occurrence of the same symptoms in patients 
with NERD, and it is reasonable to hypothesize that 
microscopic damage is responsible for the GERD-related 
symptoms in them[84]. According to this assumption, 
recent investigations have focused their attention on 
the evaluation of the presence of dilated intercellular 
spaces, considered the most important microscopic 
alteration involved in symptom perception in patients 
with GERD[85]. Recently Savarino et al[86] showed that 
the frequency of microscopic esophagitis did not differ 
between patients with FH and control subjects and was 
significantly lower in FH patients than in the EE and 
well-defined NERD patients evaluated with MII-pH.
The overall MII-pH assessment “on” or “off” PPI 
therapy is actually a matter of discussion. In a recent 
seminar, Bredenoord et al[52] affirmed that combined 
MII-pH is better performed off PPIs when the diagnosis 
of GERD has not yet been established and on-PPIs 
when the diagnosis has been already made (i.e., 
positive endoscopy for EE, MII-pH off-therapy already 
performed, BE surveillance). In particular, MII-pH off 
PPIs is useful to investigate the causes of ineffective PPI 
treatment. To confirm the presence of GERD, Hemmink 
et al[87] reported that PPI-resistant patients should 
preferably be evaluated with MII-pH monitoring after 
cessation of PPI treatment. This approach could increase 
the likelihood of observing a positive relationship 
between symptoms and reflux.
GERD is considered an important cause of laryngeal 
inflammation. Laryngoscopic examinations are very 
important to exclude abnormalities in the laryngeal 
mucosa or vocal cords (nodules or neoplastic lesions), 
but it is not sufficiently specific/sensitive to detect 
LPR[88]. We recently described that MII-pH analysis 
detected GERD at least in 40% of patients who were 
diagnosed with LPRD. In particular, MII-pH analysis was 
able to identify patients with NERD, those with HE and 
those without GERD, whereas laryngeal symptoms and 
laryngoscopic findings were not able to do so[89]. 
Finally, some interesting studies, performed by 
means of MII-pH analysis, evaluated the effectiveness 
of raft-forming gel formulation in “add-on” treatment 
for GERD symptoms. These studies have clearly demon-
strated the efficacy of raft-forming gel preparation in 
reducing the total number of refluxes and their proximal 
migration[90-92]. 
To conclude, MII-pH is able to improve the ability 
to detect GERD compared with pH-metry alone in 
patients with GERD-related symptoms. MII-pH is able 
to provide more information and to exclude GERD 
diagnosis definitively in PPI non-responder patients 
(FH). The outcomes studies are unmet clinical needs for 
determining whether MII-pH truly leads to a change in 
management.
Combined multichannel intraluminal impedance and 
manometry has been considered a very helpful device 
because it provides information about esophageal contr-
action and bolus transit simultaneously. Tutuian et al[93] 
described results from a large cohort of patients (350), 
showing a very strong correlation between dysphagia 
and incomplete bolus transit. Moreover, the largest 
defects of bolus transit were correlated with diagnoses 
of achalasia, scleroderma, distal esophageal spasm and 
IEM. Outcome studies are needed to clarify better the 
role of this technique in clinical diagnosis. 
WIRELESS PH CAPSULE (BRAVO)
The wireless pH capsule (BRAVO) is a novel technology 
able to assess esophageal exposure to acid. This device 
is placed transorally 6 cm above the EGJ during an 
upper endoscopy, usually under sedation, or 5 cm above 
the LES, previously detected by means of esophageal 
manometry[94]. The capsule transmits recording data via 
telemetry to an external receiver. This method is usually 
performed after the failure of a PPI test, alternatively 
at MII-pH or during an upper endoscopy before the 
PPI test. Capsule detachment occurs spontaneously in 
most cases between 2-3 d and 2 wk[95]. Adverse events 
or complications (severe or persistent chest pain) are 
very rare (1% to 2%)[94]. The technique is usually 
well tolerated, and the principal side effect reported 
is mild to moderate chest pain. The recording time of 
the wireless capsule is usually 48 h, showing overall 
good reproducibility between the 2 d of recording[96]. 
However, several studies have shown a relevant day-
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to-day variability responsible for discrepancies in AET 
between the first and the second days of recording[97,98]. 
The reasons for these findings remain controversial and 
are the subject of debate.
A great day-to-day variability in AET might be 
frequent during 24-h pH-metry testing. pH monitoring 
prolonged to 48 h is routinely performed with the 
BRAVO technique, and it should provide a better over-
view of esophageal acid exposure and symptom-reflux 
correlation.
The prolonged pH-monitoring period increases the 
likelihood of detecting reflux events (12.5% increase), 
potentially improving symptom association (5.2% 
increase)[99]. These data were confirmed in patients 
on anti-reflux therapy[99], in patients with endoscopy 
negative heartburn[100] and in patients with non-cardiac 
chest pain[101]. 
Overall, BRAVO is a good method for reflux mo-
nitoring, especially in patients with less frequent 
symptoms (i.e., non-cardiac chest pain) and in those 
who refuse catheter-based techniques, but it has some 
limitations, including higher cost than MII-pH and the 
possible risk of misplacement; more importantly, non-
acid reflux events cannot be detected. 
ENDOFLIP
An important property of the reflux barrier that is not 
assessed by manometry is distensibility (i.e., the ease 
with which the EGJ is opened)[102]. If pressure and 
radius can be measured simultaneously in the LES, the 
circumferential tension in the wall can be estimated, as 
it has been firstly demonstrated by McMahon et al[103].
The EndoFLIP (Endo Functional Luminal Imaging 
Probe system; Crospon Ltd., Galway, Ireland) consists 
of a polyurethane balloon (maximum volume of 60 mL) 
mounted on the distal 14 cm of a probe (length 240 
cm, diameter 25 mm) attached to the EndoFLIP unit. 
This balloon assumes a 10-cm long cylindrical shape 
with maximum diameter of 2.5 cm when filled. Along a 
7.5-cm segment within the balloon, 17 ring electrodes 
are spaced 5 mm apart to obtain 16 CSA measurements 
using an impedance planimetry technique. The probe 
also contains a solid-state pressure transducer to 
measure intra-balloon pressure. 
The EndoFLIP system provides real-time and 
dynamic information on EGJ distention that is visualized 
as cylinders of different diameters, based on instan-
taneous CSA measurements (included instant pressure 
measurements). 
Using this technique, Kwiatek et al[104] compared 
GERD patients with healthy controls, with the following 
major findings: (1) the EGJ was 2 to 3 times more 
distensible in GERD patients than controls; (2) 20- to 
30-mL distention volumes provided, in patients with 
GERD, a two- to three-fold increased EGJ distensibility, 
compared with controls; and (3) the endoscopic esti-
mation of the flap valve grade seemed poorly correlated 
with EndoFLIP measurements.
Recently, Regan et al[105] used the EndoFLIP system to 
measure upper esophageal sphincter (UES) distensibility. 
EndoFLIP provided definitive information regarding UES 
compliance without the need for fluoroscopy. The results 
regarding the anatomic parameters and physiology of 
UES were directly matched with current knowledge. Few 
data are yet available, but EndoFLIP could be able to 
provide determinant information about UES in patients 
with dysphagia before and after surgery or rehabilitation. 
DX-PH (RESTECH)
As mentioned above, the diagnosis and treatment of 
GERD are particularly difficult in cases of LPR[106]. 
Some authors have described LPR by means of 
dual-channel impedance and pH monitoring[107,108]. 
These studies have described the frequency, location, 
and direction of any gas or liquid refluxate along 
the esophagus, as well as in the hypopharynx[107]. 
Despite initial enthusiasm[108,109], outcome studies with 
impedance monitoring have been lacking, and their 
clinical significance with regard to medically recalcitrant 
LPR patients remains unclear[110].
The Dx-pH measurement system, called Restech 
(Respiratory Technology Corp., San Diego, CA, United 
States), was designed to detect aerosolized acid, thus 
identifying patients whose symptoms are due to acidic 
mist or liquid refluxing into the pharynx. Because the distal 
part containing the pH sensor does not traverse the UES, 
it is more comfortable than a conventional pH catheter, 
and it does not require esophageal manometry[17]. 
Restech has a higher frequency of measurement 
than older catheter-based pH probes and wireless pH 
probes, with a pH measurement obtained every 0.5 
s (sampling rate, 2 Hz), compared with traditional 
catheter-based pH probes, which sample every 4 s to 
5 s (at a rate of 0.2-0.25 Hz), and wireless pH probes, 
with a pH measurement every 6 s (0.17 Hz). This in-
creased sampling rate theoretically allows Restech to 
detect more reflux events, which is a characteristic that 
could prove useful in patients with LPR[111]. 
Recently, Worrell et al[112] demonstrated, that in 
patients with extraesophageal reflux symptoms who 
underwent antireflux surgery, esophageal pH monitoring 
in the proximal esophagus failed to recognize 50% 
of the patients who recorded good outcomes post-
antireflux surgery. Vailati et al[113] showed the high 
specificity and reasonable sensitivity of the Restech 
technique, which could be considered an interesting 
tool that can be used before therapy in patients with 
pharyngoesophageal reflux. In contrast, Ummarino et 
al[114] did not show any correlation, although chronic 
coughing was the only symptom reported by patients, 
and when they compared MII-pH and Restech, the 
superiority of the first technique seemed clear. Similarly, 
Becker et al[115] evaluated, in a prospective, single-center 
trial, the differences between MII-pH and Dx-pH. They 
demonstrated that acid pharyngeal pH levels detected 
with Dx-pH were not correlated with GERD, and acid 
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esophageal reflux episodes did not result in pharyngeal 
pH alterations. Mazzoleni et al[116], observed a very 
poor correlation between Dx-pH probe oropharyngeal 
monitoring and MII-pH in a group of 68 patients. 
Until now, the use of Dx-pH recordings could not 
be recommended in clinical practice, given the discre-
pancies between traditional MII-pH monitoring and the 
current technologies used to measure oro-pharyngeal 
pH events.
PEP-TEST
Recent studies have shown that patients with LPR do 
not reap great benefit from PPI therapy because, at this 
level, the damage is not mediated by acid but rather 
by pepsin[117]. For this reason, it was recently decided 
to search for pepsin as a marker of reflux because 
the enzyme is secreted only by gastric main cells[118]; 
therefore, its presence above UES is a certain sign of 
GERD.
The pepsin lateral flow device (LFD), also called 
the PEP-Test (RDBiomed, Hull, United Kingdom), is 
a rapid, non-invasive test to detect salivary pepsin 
as a surrogate marker for GERD. The PEP-Test is an 
immunological in-vitro diagnostic medical device that 
contains two pepsin monoclonal antibodies; this test 
is able to detect pepsin in a clinical sample of saliva/
sputum quickly and easily; the limit of detection is 16 
ng/mL of pepsin. The patient must collect 30 mL of 
saliva, and this sample is centrifuged at 4000 rpm for 5 
min; then, 80 μL from the surface layer are drawn up 
and mixed with a buffer solution using a vortex mixer. 
The sample obtained is applied in the circular well of the 
PEP-Test device, and after a few minutes, it is possible 
to check for the presence of pepsin: If it occurs on 
antigen-antibody binding, two blue lines appear on the 
display, while if pepsin is not present, it will be possible 
to see only the control line. The blue lines are visible on 
the display because the monoclonal antibody is directly 
labelled with blue latex beads, which detach at the time 
of Ag-Ab binding. Saritas Yuksel et al[19] evaluated the 
PEP-Test (defined as ELISA LFD) in 47 patients using 
pH-metry as a reference standard. The results were 
compared with a control population, which underwent 
only the PEP-Test, which has sensitivity and a specificity 
of 87% (Figure 5).
More recently Hayat et al[119] compared the PEP-
test with MII-pH and showed a higher prevalence and 
concentration of salivary pepsin in patients with GERD 
or HE, compared with patients with FH and healthy 
controls. The authors suggested that salivary pepsin 
might complement questionnaires in the office-based 
diagnosis of patients with GERD-related symptoms.
The most important advantages of the PEP-Test 
are its low cost, its non-invasiveness, and, not to be 
underestimated, its feasibility while the patient is 
undergoing PPI therapy. However, given the very limited 
data available in the medical literature, further studies 
are needed to understand and assess the clinical utility 
of this test.
CONCLUSION
The reflux of gastric contents into the esophagus results 
in a broad and varied GERD spectrum. Thus, advances 
in the diagnosis of GERD represent the necessary 
progress in clinical investigation and therapeutic manage-
ment as well as progress for more-in-depth assessment 
of the underlying pathophysiological mechanisms.
The pathogenesis of GERD is multifactorial, including 
esophageal motility abnormalities of which the most 
important are TLESRs and hypotensive LES and IEM. 
Recently, the role of esophageal dysmotility has gained 
relevant interest, showing an increased prevalence 
with increasing severity of GERD, from NERD to EE 
and BE[120]. To date, HRM is the gold standard for 
characterizing esophageal motility disorders. Indeed, 
HRM improves characterization of LES zones and 
esophageal body motility, increasing diagnostic yield and 
accuracy[121]. Moreover, HRM must be regarded as the 
new gold standard for detecting TLESRs[43]. However, 
the value of HRM in clinical practice has yet to be 
established fully Exclusion of severe esophageal motility 
disorders (i.e., achalasia) is important because such 
diseases can present with heartburn and regurgitation, 
which could lead to an erroneous diagnosis of GERD[122]. 
Ambulatory MII-pH has become the gold standard 
for investigating GERD, owing mainly to its ability to 
detect both acid and non-acid reflux[68,123]. Of particular 
importance, MII-pH has enabled the subdivision of 
patients with NERD into different subsets, including 
patients with an excess of acid and those with sym-
ptomatic non-acid reflux, and MII-pH has the ability 
to identify patients with FH whose symptoms are not 
GERD related and who must be excluded from the 
realm of GERD[6,56,109]. 
Moreover, diagnosing patients with HE to non-acid 
reflux, MII-pH has contributed to narrowing down the 
population of patients with FH[70]. Recently, it has been 
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Figure 5  The picture shows the lateral flow device test to detect the 
presence of pepsin in saliva (PEP-test; RDBiomed, Hull, United Kingdom). 
A: A negative test indicates that no pepsin was detected in clinical sample (only C 
line is colored); B: A positive test, it indicates that pepsin is present in the sample 
(saliva/sputum). In the both T and C line are colored.
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demonstrated that a more-in-depth pathophysiological 
evaluation of MII-pH tracings, including baseline 
impedance levels and PSPW index evaluation, could be 
helpful in better investigating patients with heartburn 
and appropriately identifying those with reflux disease 
and particularly those with HE, when symptom-reflux 
association analysis fails to do so[5,78,81]. 
According to the Montreal Classification, extra-
esophageal symptoms of GERD can occur, such as 
hoarseness, coughing, and asthma[2]. However, establi-
shing that extra-esophageal symptoms caused by GERD 
can be difficult, and in this context, the advent of new 
technologies deserves careful consideration. The Dx-
pH measurement system is a sensitive and minimally 
invasive device for detecting acidic refluxate in the 
oropharynx. The PEP-Test is a sensitive and specific in 
vitro diagnostic test that allows for the rapid detection of 
pepsin, a marker of reflux, in a clinical sample. Overall, 
further studies are warranted to substantiate the clinical 
roles of these new technologies in diagnosing GERD.
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